Halozyme Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| HALO | BMRN | REGN | LGND | ROIV | URGN | |
|---|---|---|---|---|---|---|
| Market cap | 14.79B | 11.06B | 96.28B | 6.32B | 27.61B | 1.40B |
| P/E (TTM) | 38.1 | — | 20.6 | 127.0 | — | — |
| Forward P/E | 12.2 | 9.0 | 13.2 | 25.9 | -27.5 | 10.4 |
| Price/book | 103.5 | 1.8 | 2.8 | 6.6 | 6.5 | -13.2 |
| Dividend yield | — | — | 0.40% | — | — | — |
| 1-year change | +90.58% | +10.20% | +51.10% | +51.82% | +85.85% | +78.15% |
| Today | +1.34% | +2.64% | −4.39% | +0.83% | +6.08% | −16.45% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All HALO news ›Halozyme Therapeutics (HALO) Q3 earnings report preview: what to look for
Biopharmaceutical drug delivery company Halozyme Therapeutics HALO will be announcing earnings results this Thursday after market hours. Here’s what you need to know. Halozyme Therapeutics beat analysts’ revenue expectations last quarter,…
Head-To-Head Comparison: Valion Bio, Inc. Common Stock (NASDAQ:VBIO) versus Halozyme Therapeutics (NASDAQ:HALO)
Posted by Tristan Rich on Oct 30th, 2026 Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) and Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) are both healthcare companies, but which is the better stock? We will compare…
What Did Halozyme Stock Investors Miss Before The Run?
Halozyme Reported Record Royalties In October 2024 It was, and management pointed this out on a call held almost a year before the run. Partners use ENHANZE to administer drugs such as DARZALEX and VYVGART Hytrulo as under-the-skin…
Stocks To Watch: Halozyme Therapeutics Sees RS Rating Rise To 92
BREAKING: Futures Rise; Musk Warns On Neocloud Rivals Investors.com will undergo scheduled maintenance from 6:00 PM ET to 9:00 PM ET and some features may be unavailable. We apologize for any inconvenience. On Thursday, Halozyme…
Halozyme Therapeutics, Inc. (HALO) – What Are Researchers Saying About This Stock?
Posted by Defense World Staff on Oct 25th, 2026 Check Out Our Latest Stock Report on Halozyme Therapeutics Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and…
Halozyme’s Strong Earnings Growth Sends Shares Higher
Halozyme Therapeutics, Inc. (HALO) shares are up 910% since March 2014. It’s no wonder HALO shares are up 85% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the…
Halozyme Therapeutics, Inc. $HALO Stock Position Cut by First Citizens Bank & Trust Co.
Posted by Defense World Staff on Oct 18th, 2026 Here are the key news stories impacting Halozyme Therapeutics this week: View Our Latest Report on HALO Halozyme licenses its technology to pharmaceutical and biotechnology companies, which…
Halo SuperTrend | NAL
Halo SuperTrend is a volatility-adaptive trend framework combining a Zero-Lag Exponential Moving Average (ZLEMA), Average True Range (ATR), and a GARCH-based conditional volatility model. Conventional SuperTrend indicators construct their…
Inside Edge’s Todd Gordon: Halozyme Therapeutics are beating estimates; raised full-year guidance
CNBC Inside Edgeâs Todd Gordon: Halozyme Therapeutics are beating estimates; raised full-year guidance
HALO Stock Climbs As Dutch Court Injunction Lifts Bullish Bets
Halozyme Therapeutics Inc. stocks have been trading up by 6.57 percent following strong sentiment around its key drug pipeline. Halozyme Therapeutics Inc. is trading like a steady grinder, not a meme rocket. Over the last few weeks, HALO…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stockstotrade.com3
- defenseworld.net2
- stocktitan.net2
- themarketsdaily.com2
- cnbc.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 17 articles, not a forecast.